Maria Flavia Di Renzo

List of Publications by Year
in descending order

85 papers	5,570 citations	117625 34 h-index	79698 73 g-index
85 all docs	85 docs citations	85 times ranked	6351 citing authors

#	Article	IF	Citations
1	Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth.. Journal of Cell Biology, 1992, 119, 629-641.	5.2	1,282
2	Tyrosine kinase receptor indistinguishable from the c-met protein. Nature, 1989, 339, 155-156.	27.8	465
3	Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas. Oncogene, 2000, 19, 1547-1555.	5.9	314
4	Overexpression of theMET/HGF receptor in ovarian cancer. International Journal of Cancer, 1994, 58, 658-662.	5.1	208
5	Overexpression and activation of hepatocyte growth factor/scatter factor in human non-small-cell lung carcinomas. British Journal of Cancer, 1996, 74, 1862-1868.	6.4	191
6	Overexpression of the RON gene in human breast carcinoma. Oncogene, 1998, 16, 2927-2933.	5.9	190
7	Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression. British Journal of Cancer, 1993, 68, 746-750.	6.4	184
8	Mitochondrial succinate is instrumental for HIF1Î± nuclear translocation in SDHA-mutant fibroblasts under normoxic conditions. Human Molecular Genetics, 2005, 14, 3263-3269.	2.9	146
9	Overexpression of the met/HGF receptor in renal cell carcinomas. , 1996, 69, 212-217.		127
10	MET Overexpression Turns Human Primary Osteoblasts into Osteosarcomas. Cancer Research, 2006, 66, 4750-4757.	0.9	123
11	Genetic and Expression Analysis of MET, MACC1, and HGF in Metastatic Colorectal Cancer: Response to Met Inhibition in Patient Xenografts and Pathologic Correlations. Clinical Cancer Research, 2011, 17, 3146-3156.	7.0	113
12	The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Experimental Cell Research, 2003, 288, 382-389.	2.6	104
13	A positive feedback loop between hepatocyte growth factor receptor and Î²-catenin sustains colorectal cancer cell invasive growth. Oncogene, 2007, 26, 1078-1087.	5.9	103
14	Truncated RON Tyrosine Kinase Drives Tumor Cell Progression and Abrogates Cell-Cell Adhesion Through E-Cadherin Transcriptional Repression. Cancer Research, 2004, 64, 5154-5161.	0.9	96
15	Novel somatic mutations of the MET oncogene in human carcinoma metastases activating cell motility and invasion. Cancer Research, 2002, 62, 7025-30.	0.9	92
16	Caveolin-1 Reduces Osteosarcoma Metastases by Inhibiting c-Src Activity and Met Signaling. Cancer Research, 2007, 67, 7675-7685.	0.9	81
17	p145, a protein with associated tyrosine kinase activity in a human gastric carcinoma cell line.. Molecular and Cellular Biology, 1988, 8, 3510-3517.	2.3	78
18	Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid. Endocrine Pathology, 2000, 11, 19-30.	9.0	72

#	Article	IF	Citations
19	Role of the MET/HGF receptor in proliferation and invasive behavior of osteosarcoma. FASEB Journal, 2003, 17, 1162-1164.	0.5	72
20	Spontaneous feline mammary carcinoma is a model of HER2 overexpressing poor prognosis human breast cancer. Cancer Research, 2005, 65, 907-12.	0.9	72
21	Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium. Journal of Endocrinological Investigation, 1995, 18, 134-139.	3.3	63
22	Expression Profiling in Progressive Stages of Fumarate-Hydratase Deficiency: The Contribution of Metabolic Changes to Tumorigenesis. Cancer Research, 2010, 70, 9153-9165.	0.9	63
23	Negative/Low Expression of the Met/Hepatocyte Growth Factor Receptor Identifies Papillary Thyroid Carcinomas with High Risk of Distant Metastases. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2322-2328.	3.6	63
24	Sparsely-connected autoencoder (SCA) for single cell RNAseq data mining. Npj Systems Biology and Applications, 2021, 7, 1.	3.0	53
25	Hepatocyte Growth Factor Sensitizes Human Ovarian Carcinoma Cell Lines to Paclitaxel and Cisplatin. Cancer Research, 2004, 64, 1744-1750.	0.9	47
26	HSP27 is required for invasion and metastasis triggered by hepatocyte growth factor. International Journal of Cancer, 2014, 134, 1289-1299.	5.1	44
27	ERÎ± as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 7420-7425.	7.1	43
28	TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin. Gynecologic Oncology, 2015, 138, 627-633.	1.4	43
29	Detection ofMET oncogene/hepatocyte growth factor receptor in lymph node metastases from head and neck squamous cell carcinomas. European Archives of Oto-Rhino-Laryngology, 1997, 254, S138-S143.	1.6	42
30	p38 MAPK turns hepatocyte growth factor to a death signal that commits ovarian cancer cells to chemotherapy-induced apoptosis. International Journal of Cancer, 2006, 118, 2981-2990.	5.1	38
31	A Mouse Model of Pulmonary Metastasis from Spontaneous Osteosarcoma Monitored In Vivo by Luciferase Imaging. PLoS ONE, 2008, 3, e1828.	2.5	38
32	CD99 Drives Terminal Differentiation of Osteosarcoma Cells by Acting as a Spatial Regulator of ERK 1/2. Journal of Bone and Mineral Research, 2014, 29, 1295-1309.	2.8	37
33	Immunological detection of proteins phosphorylated at tyrosine in cells stimulated by growth factors or transformed by retroviral-oncogene-coded tyrosine kinases. FEBS Journal, 1986, 158, 383-391.	0.2	36
34	Control of invasive growth by the HGF receptor family. Journal of Cellular Physiology, 1997, 173, 183-186.	4.1	35
35	met oncogene activation qualifies spontaneous canine osteosarcoma as a suitable preâ€clinical model of human osteosarcoma. Journal of Pathology, 2009, 218, 399-408.	4.5	34
36	The cellular apoptosis susceptibilityCAS/CSE1Lgene protects ovarian cancer cells from death by suppressing RASSF1C. FASEB Journal, 2012, 26, 2446-2456.	0.5	34

#	Article	IF	Citations
37	Heatâ€shock protein 27 (HSP27, HSPB1) is upâ€regulated by MET kinase inhibitors and confers resistance to METâ€targeted therapy. FASEB Journal, 2014, 28, 4055-4067.	0.5	34
38	Heat-shock protein 27 (HSP27, HSPB1) is synthetic lethal to cells with oncogenic activation of MET, EGFR and BRAF. Molecular Oncology, 2017, 11, 599-611.	4.6	32
39	Deletion in a (T)8 microsatellite abrogates expression regulation by 3'-UTR. Nucleic Acids Research, 2003, 31, 6561-6569.	14.5	30
40	The Therapeutic Potential of Hepatocyte Growth Factor to Sensitize Ovarian Cancer Cells to Cisplatin and Paclitaxel In vivo. Clinical Cancer Research, 2007, 13, 2191-2198.	7.0	29
41	Cells Lacking the Fumarase Tumor Suppressor Are Protected from Apoptosis through a Hypoxia-Inducible Factor-Independent, AMPK-Dependent Mechanism. Molecular and Cellular Biology, 2012, 32, 3081-3094.	2.3	29
42	IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. European Journal of Cancer, 2013, 49, 964-973.	2.8	29
43	Feline STK gene expression in mammary carcinomas. Oncogene, 2002, 21, 1785-1790.	5.9	28
44	Immunofluorescence localization of phosphotyrosine containing proteins in RSV-transformed mouse fibroblasts*1. Experimental Cell Research, 1984, 154, 112-124.	2.6	27
45	Hepatocyte growth factor installs a survival platform for colorectal cancer cell invasive growth and overcomes p38 MAPK-mediated apoptosis. Cellular Signalling, 2006, 18, 1967-1976.	3.6	27
46	Genes regulated by hepatocyte growth factor as targets to sensitize ovarian cancer cells to cisplatin. Molecular Cancer Therapeutics, 2006, 5, 1126-1135.	4.1	27
47	The MET oncogene transforms human primary bone-derived cells into osteosarcomas by targeting committed osteo-progenitors. Journal of Bone and Mineral Research, 2012, 27, 1322-1334.	2.8	27
48	p38 MAPK downregulates phosphorylation of Bad in doxorubicin-induced endothelial apoptosis. Biochemical and Biophysical Research Communications, 2006, 347, 781-790.	2.1	25
49	Characterization of stable spontaneous metastatic variant lines of RSV-transformed mouse fibroblasts. International Journal of Cancer, 1982, 30, 751-757.	5.1	24
50	PIM2 Kinase Is Induced by Cisplatin in Ovarian Cancer Cells and Limits Drug Efficacy. Journal of Proteome Research, 2014, 13, 4970-4982.	3.7	22
51	Lipid characteristics of RSV-transformed Balb/c 3T3 cell lines with different spontaneous metastatic potentials. Lipids, 1989, 24, 685-690.	1.7	21
52	AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells. Experimental Cell Research, 2013, 319, 2627-2636.	2.6	21
53	A cancerâ€predisposing â€œhot spotâ€•mutation of the fumarase gene creates a dominant negative protein. International Journal of Cancer, 2008, 122, 947-951.	5.1	20
54	TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. Journal of Ovarian Research, 2019, 12, 17.	3.0	20

#	Article	IF	Citations
55	Metastatic clones selected from an RSV-induced mouse sarcoma share a common marker chromosome. International Journal of Cancer, 1983, 31, 455-461.	5.1	19
56	Proteins phosphorylated on tyrosine as markers of human tumor cell lines. International Journal of Cancer, 1987, 39, 482-487.	5.1	18
57	The stress phenotype makes cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase. Oncotarget, 2014, 5, 5992-6002.	1.8	17
58	Evidence for autocrine activation of a tyrosine kinase in a human gastric carcinoma cell line. Journal of Cellular Biochemistry, 1988, 38, 229-236.	2.6	15
59	Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas. BMC Veterinary Research, 2013, 9, 80.	1.9	15
60	Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer. Oncotarget, 2016, 7, 26181-26191.	1.8	15
61	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. Oncotarget, 2016, 7, 40073-40084.	1.8	15
62	Role of heterochromatin variation in the instability of a marker chromosome during tumor progression. Cancer Genetics and Cytogenetics, 1985, 15, 283-291.	1.0	14
63	Protein Tyrosine Kinases Associated with Human Malignancies. Annals of the New York Academy of Sciences, 1987, 511, 256-261.	3.8	14
64	Amplification of repeat-containing transcribed sequences (ARTS): a transcriptome fingerprinting strategy to detect functionally relevant microsatellite mutations in cancer. Nucleic Acids Research, 2003, 31, 33e-33.	14.5	14
65	Tyrosine Kinase and Control of Cell Proliferation. The American Review of Respiratory Disease, 1990, 142, S16-S19.	2.9	13
66	Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism. Oncotarget, 2016, 7, 712-728.	1.8	13
67	Protein phosphorylation at tyrosine residues INv-abl transformed mouse lymphocytes and fibroblasts. International Journal of Cancer, 1986, 37, 623-628.	5.1	12
68	Fumarase tumor suppressor gene and MET oncogene cooperate in upholding transformation and tumorigenesis. FASEB Journal, 2010, 24, 2680-2688.	0.5	12
69	Characterization of T lymphocytes mediatingin vivo protection against RSV-induced murine sarcomas. International Journal of Cancer, 1983, 31, 757-764.	5.1	11
70	The integrin-linked kinase-associated phosphatase (ILKAP) is a regulatory hub of ovarian cancer cell susceptibility to platinum drugs. European Journal of Cancer, 2016, 60, 59-68.	2.8	10
71	Organization of cytoskeleton and fibronectin matrix in rous sarcoma virus (RSV)-transformed fibroblast lines with different metastatic potential. European Journal of Cancer & Clinical Oncology, 1985, 21, 85-96.	0.7	9
72	Patient-Derived Cancer Models. Cancers, 2020, 12, 3779.	3.7	9

#	Article	IF	Citations
73	Constitutively activatedneu oncoprotein tyrosine kinase interferes with growth factor-induced signals for gene activation. Journal of Cellular Biochemistry, 1991, 45, 69-81.	2.6	7
74	PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma. Cells, 2020, 9, 442.	4.1	7
75	Monoclonal Antibodies to the Collagen Binding Domain of Human Plasma Fibronectin. Pathobiology, 1984, 52, 225-236.	3.8	4
76	Daily administration of low molecular weight heparin increases Hepatocyte Growth Factor serum levels in gynaecological patients: pharmacokinetic parameters and clinical implications. BMC Research Notes, 2012, 5, 517.	1.4	3
77	High Chemotactic Motility and Growth in Hard Agar of a Variant of RSV-Transformed Fibroblasts are Lost in Late Passages. Tumori, 1988, 74, 1-6.	1.1	2
78	Identification of a protein cross-reacting with anti-phosphotyrosine antibodies in yeast insoluble cytoplasmic matrices. Biochemical and Biophysical Research Communications, 1989, 160, 887-896.	2.1	2
79	Heat Shock Protein 27 (HSP27, HSPB1) Is Up-Regulated by Targeted Agents and Confers Resistance to Both Targeted Drugs and Chemotherapeutics. Heat Shock Proteins, 2015, , 17-25.	0.2	1
80	Translational Research in Ovarian Cancer. Cancers, 2020, 12, 3676.	3.7	1
81	Changeable chemotactic response of metastatic variant lines of RSV-transformed mouse fibroblasts. Cell Biology International Reports, 1986, 10, 191-191.	0.6	0
82	Abstract 215: CSE1L as a potential target to sensitize ovarian cancer cells to cisplatin. , 2010, , .		0
83	Abstract B42: Heat Shock Protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibition and limits the effectiveness of inhibitors. Clinical Cancer Research, 2012, 18, B42-B42.	7.0	0
84	Abstract B28: The stress phenotype makes ovarian cancer cells addicted to CDT2, a substrate receptor of the CRL4 ubiquitin ligase. , 2013, , .		0
85	Abstract C131: HSP27 is necessary in cells showing oncogene hyper-activation.. , 2013, , .		0